Tag: NeuroOncology
PRESENTATION OF UPDATED POSITIVE INTERIM RESULTS OF NOX-A12 GLORIA PHASE 1/2 IN BRAIN CANCER AT THE 2022 ANNUAL MEETING OF THE SOCIETY FOR NEURO-ONCOLOGY (SNO) – 11/19/2022 at 01: 30
• 100% radiographic partial response rate achieved in patients treated with NOX A12 + radiotherapy + bevacizumab. 83% of patients show durable mRANO responses.• Of the 6 patients treated, 2…
TME Pharma Announces Participation and Presentation at the Society for Neuro-Oncology 2022 Annual Meeting – 09/20/2022 at 6:00 PM
To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected] Presentation information: Presentation title: Dual inhibition of post-radiogenic angio-vasculogenesis…